Del Mar Pharmaceuticals is developing and commercializing cancer therapies in new orphan drug indications for patients failing modern targeted or biologic treatments. The company’s lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083’s clinical research is sponsored by the U.S. National Cancer Institute and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. For more information visit the company’s Web site at www.delmarpharma.com
Let us hear your thoughts below: